• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > GlaxoSmithKline > January 25, 2011

      GlaxoSmithKline Starts 2 Phase III Studies In Advanced/Metastatic Melanoma

      Posted Atonline.wsj.com

      LONDON (Dow Jones)--GlaxoSmithKline (GSK.LN), the drug giant, Monday announced the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation.

      MAIN FACTS:

      The studies will separately assess the efficacy and safety of two investigational agents, GSK2118436 and GSK1120212, to determine their individual ability to stop or slow the progression of skin cancer in patients whose tumours contain a BRAF V600 mutation, which occurs in 50 to 60 percent of melanoma patients.

      Commencement of these studies confirms previously announced plans to progress these assets into Phase III.

      Shares at 1305 GMT up 1.34% at 1171.50 pence valuing the company at GBP60.87 billion.

      Jan 25, 2011


       

      Share this Article!

    Back to top^